Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 115   

Articles published

JNJ 95.38 +0.30 (0.32%)
price chart
America's Most Admired Lawbreaker
On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more ...
Johnson & Johnson Announces Completion of Cordis Divestiture to Cardinal Health
NEW BRUNSWICK, N.J., Oct. 4, 2015 /PRNewswire/ -- Johnson & Johnson JNJ, +0.11% today announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.
Cardinal Healt acquires Johnson & Johnson's Cordis business
Biotech Movers Update: Johnson & Johnson (NYSE:JNJ) Valeant Pharmaceuticals ...
Johnson & Johnson (JNJ) reported the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.
Pipeline Drugs Need To Fire For Johnson & Johnson's Oncology Business
Johnson & Johnson's oncology business is not as strong as that of some of the other pharmaceutical companies, at least as far as future expected growth is concerned.
Johnson & Johnson (JNJ) Closes 0.31% Up on the Day for October 09
Johnson & Johnson currently has a total float of 2.77 billion shares and moves n/a a day, on average. The stock opened at $95.14 on October 09 and traded between a low of $94.78 and a high of $95.96.
Johnson & Johnson starts clinical trial in Sierra Leone for Ebola vaccine
Business. Johnson & Johnson starts clinical trial in Sierra Leone for Ebola vaccine. By: The Associated Press Posted: 10/9/2015 6:02 AM | Last Modified: 10/9/2015 12:24 PM | Comments: 0. Tweet; Post; Reddit; ShareThis; Print; Email.
Johnson & Johnson Looks to IBM's Watson to Predict Patient Outcomes
Johnson & Johnson JNJ +0.11% is working with International Business Machines Corp.IBM +1.46%to create consumer-focused technology apps that apply artificial intelligence to health data, in this case to provide patients with a virtual coach.
Did Eli Lilly Just Get a Leg Up on Johnson & Johnson?
This is especially ill-timed for Johnson & Johnson (NYSE:JNJ), which markets a similar drug that has been raising safety concerns lately.
Johnson & Johnson: JNJ Stock Still Has Plenty of Long-Term Potential
JohnsonJohnsonLogo e1282585796958 Johnson & Johnson: JNJ Stock Still Has Plenty of Long Term Potential A multipart Huffington Post piece ripped the pharma company for covering up negative side effects of one of its drugs and accused the company ...
Johnson & Johnson Short Interest Update  Money Flow Index
Johnson & Johnson's "Hold" Rating Reaffirmed at Bank of ...  Financial Wisdom Works
Johnson & Johnson: Currency Not Only Headwind
On the heels of a weak second-quarter report, Johnson & Johnson (JNJ) is poised to announce further revenue and earnings declines for its third quarter.